GBS Inc. (NASDAQ:GBS), soon to change its name to Intelligent Bio Solutions Inc. (NASDAQ: IBSS), noted its shares creep up Wednesday. The company, a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, today announced that the Company has formally changed its name from GBS Inc. to Intelligent Bio Solutions Inc. and will begin trading under the new symbol “IBSS” on Nasdaq effective with the open of the market on Thursday, October 27.
Until now, Steven Boyages has acted as both Chairman and interim Chief Executive Officer during this important transition phase. Given the growth and commercialization phase IBSS expects to enter, the Board of Directors is announcing several new executive appointments, including the role of Chief Executive Officer and two new members of the Intelligent Bio Solutions Board of Directors.
Steven Boyages will continue as Chairman of the Board and has reappointed Harry Simeonidis as Chief Executive Officer. Simeonidis has more than 25 years of experience in health-care, pharmaceutical and life sciences across various senior management positions throughout Asia, Australia, and New Zealand.
Before joining Intelligent Bio Solutions, he was the General Manager, Surgery, Asia Pacific, at GE Healthcare where he oversaw significant expansion of the business’ market share. Prior to this, Simeonidis spent nine years as the President and CEO of GE Healthcare ANZ. Simeonidis also served as non-executive Director of Farmaforce Limited, a publicly traded contract sales organization servicing the Australian pharmaceutical industry.
GBS shares picked up three quarters of a cent, or 1.6%, soon after Wednesday’s opening bell to 48 cents.
